Shi et al. found that in PDGFRβ-upregulated, Vemurafenib-resistant BRAF-mutated melanoma cell lines, a combined BRAF, PI3K, and mTORC1/2 inhibition suppresses the compensatory signaling at the basis of therapeutic resistance, resulting in a highly synergistic growth inhibitory response in vitro [299]. This evidence concerns the gene PIK3CG and melanoma.